114 related articles for article (PubMed ID: 30242670)
1. European research trends in nuclear medicine.
Inubushi M; Tatsumi M; Yamamoto Y; Kato K; Tsujikawa T; Nishii R
Ann Nucl Med; 2018 Nov; 32(9):579-582. PubMed ID: 30242670
[TBL] [Abstract][Full Text] [Related]
2. Topics of nuclear medicine research in Europe.
Inubushi M; Kaneta T; Ishimori T; Imabayashi E; Okizaki A; Oku N
Ann Nucl Med; 2017 Oct; 31(8):571-574. PubMed ID: 28744708
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
[TBL] [Abstract][Full Text] [Related]
4. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
[TBL] [Abstract][Full Text] [Related]
5. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
6. Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging.
Akamatsu G; Ikari Y; Nishio T; Nishida H; Ohnishi A; Aita K; Sasaki M; Sasaki M; Senda M
Ann Nucl Med; 2016 Jan; 30(1):18-28. PubMed ID: 26337533
[TBL] [Abstract][Full Text] [Related]
7. Biological characters of [18F]O-FEt-PIB in a rat model of Alzheimer's disease using micro-PET imaging.
Zheng MQ; Yin DZ; Zhang L; Lei B; Cheng DF; Cai HC; Han YJ; Wu MX; Zhang H; Wang J
Acta Pharmacol Sin; 2008 May; 29(5):548-54. PubMed ID: 18430362
[TBL] [Abstract][Full Text] [Related]
8. Comparability of [
Rodriguez-Vieitez E; Leuzy A; Chiotis K; Saint-Aubert L; Wall A; Nordberg A
J Cereb Blood Flow Metab; 2017 Feb; 37(2):740-749. PubMed ID: 27107028
[TBL] [Abstract][Full Text] [Related]
9. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
[TBL] [Abstract][Full Text] [Related]
11. From the respective expert viewpoints of the ANM specialty editors.
Inubushi M; Shidahara M; Takahashi Y; Ogawa M; Kiyono Y
Ann Nucl Med; 2019 Dec; 33(12):877-880. PubMed ID: 31745811
[TBL] [Abstract][Full Text] [Related]
12. Nuclear medicine practice in Japan: a report of the seventh nationwide survey in 2012.
Kinuya S; Kuwabara Y; Inoue K; Sakamoto S; Shimosegawa E; Takeoka K; Takeda Y; Toyama H; Niio Y; Nishiyama Y; Yoshinaga K; Yoshimura M
Ann Nucl Med; 2014 Dec; 28(10):1032-8. PubMed ID: 25113149
[TBL] [Abstract][Full Text] [Related]
13. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
Gulyás B; Halldin C
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
[TBL] [Abstract][Full Text] [Related]
14. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
Shea YF; Ha J; Lee SC; Chu LW
Hong Kong Med J; 2016 Aug; 22(4):327-33. PubMed ID: 27313272
[TBL] [Abstract][Full Text] [Related]
15. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
[TBL] [Abstract][Full Text] [Related]
16. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?
Vallabhajosula S; Solnes L; Vallabhajosula B
Semin Nucl Med; 2011 Jul; 41(4):246-64. PubMed ID: 21624560
[TBL] [Abstract][Full Text] [Related]
17. Comparison of [
Lowe VJ; Lundt E; Knopman D; Senjem ML; Gunter JL; Schwarz CG; Kemp BJ; Jack CR; Petersen RC
Neuroimage Clin; 2017; 16():295-302. PubMed ID: 28856092
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
[TBL] [Abstract][Full Text] [Related]
19. Impact of molecular imaging on the diagnostic process in a memory clinic.
Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
[TBL] [Abstract][Full Text] [Related]
20. Florbetapir F 18 for brain imaging of β-amyloid plaques.
Romano M; Buratti E
Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
